Immutep Ltd Stock Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Sales 2024 * | 3.19M 2.05M | Sales 2025 * | 16.98M 10.9M | Capitalization | 416M 267M |
---|---|---|---|---|---|
Net income 2024 * | -45M -28.88M | Net income 2025 * | -43M -27.6M | EV / Sales 2024 * | 106 x |
Net cash position 2024 * | 76.33M 48.99M | Net cash position 2025 * | 47.15M 30.26M | EV / Sales 2025 * | 21.7 x |
P/E ratio 2024 * |
-8.82
x | P/E ratio 2025 * |
-9.61
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
1st Jan change | Capi. | |
---|---|---|
-1.82% | 41.35B | |
+42.78% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |